ABLYNX PROVIDES BUSINESS UPDATE FOR THE THIRD QUARTER 2010
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 18 November 2010 - Ablynx [Euronext Brussels: ABLX] today
provides its non-audited business update in compliance with the EU transparency
directive. This report summarizes material events and Ablynx's financial
position for the third quarter of 2010. It has been approved by the Board of
Directors.
Q3 2010 Highlights
* Initiated an open-label, randomized Phase II study for patients with
thrombotic thrombocytopenic purpura (TTP), in Europe and North America, with
its anti-von Willebrand factor (vWF) Nanobody(®) (ALX-0081/ALX-0681)
* Progressed the Phase II trial for its anti-vWF programme (ALX-0081) in
patients with acute coronary syndrome (ACS) undergoing percutaneous coronary
intervention (PCI)
* Pfizer completed recruitment for its lead anti-TNF-alpha Nanobody, ATN-103,
currently in a Phase II study in patients with rheumatoid arthritis (RA)
* Reported positive safety data for its ongoing Phase I study with ALX-0141, a
Nanobody targeting Receptor Activator of Nuclear Factor kappa B Ligand
(RANKL) which plays a key role in bone remodeling
* Received a ?3.0 million milestone payment as part of its strategic alliance
with Boehringer Ingelheim
* Received ?1.0 million from Novartis for licenses to further develop and
commercialize Nanobodies against two complex targets
* Received a Notice of Allowance from the US Patent and Trademark office for
its patent application protecting the composition of matter of its
programmes targeting vWF (ALX-0081 and ALX-0681)
* Revenues were ?17 million for the period January-September
* ?109.5 million in cash, cash equivalents and restricted cash at 30 September
2010
Nine Months 2010 Financial Update
Revenues for the first nine months were ?17 million (2009: ?21.9 million).
Expenses increased by 5% to ?39.5 million (2009: ?37.5 million). This resulted
in a net loss for the first nine months of ?21.5 million (2009: ?13.5 million).
The Company's cash, cash equivalents and restricted cash were ?109.5 million at
30 September 2010 (2009: ?93.7million).
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:edwin.moses(at)ablynx.com
Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 11
e:wim.ottevaere(at)ablynx.com
Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0) 479 49 06 03
e:marieke.vermeersch(at)ablynx.com
[HUG#1463557]
Complete version of the press release:
http://hugin.info/137912/R/1463557/402263.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2010 - 07:31 Uhr
Sprache: Deutsch
News-ID 48885
Anzahl Zeichen: 3632
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 260 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX PROVIDES BUSINESS UPDATE FOR THE THIRD QUARTER 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
